Ann: DEP irinotecan clinical data presented at AACR meeting, page-9

Looks like pretty impressive interim data to me

new positive data for DEP^® irinotecan in the platinum-resistant ovarian cancer patient cohort, where the objective response rate (ORR2) in patients dosed every 2 weeks (Q2W) has increased from the previously reported 29% to 43%. In addition to this impressive efficacy, the duration of responses to DEP^® irinotecan treatment in these heavily pre-treated ovarian cancer patients, with tumour shrinkage of up to 60%, now have durations of up to 45 weeks, compared with 36 weeks reported previously

DEP^® irinotecan’s impressive ORR of 43% in these heavily pre-treated patients compares very favourably to standard-of-care single-agent therapies for platinum-resistant ovarian cancer, including paclitaxel (Taxol^®), topotecan (Hycamtin^®), gemcitabine (Gemzar^®) or pegylated liposomal doxorubicin (Caelyx^®), which report ORRs ranging from ~9 to 16%